The United States Immunodeficiency Network (USIDNET) is a research consortium established to advance scientific research in the field of primary immunodeficiency (PI). USIDNET is an National Institutes of Health (NIH)-funded research program of the Immune Deficiency Foundation (IDF).

Pfizer's purpose is breakthroughs that change patients’ lives. We pursue that goal relentlessly and innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today.

Leadiant Biosciences, Inc., is a U.S. research-based pharmaceutical company that dedicates considerable scientific and financial resources to the research, development, and distribution of novel and effective therapies to address the needs of people living with rare diseases.

Chiesi manufactures Revcovi, the only recombinant adenosine deaminase (ADA) approved to treat ADA-SCID in the U.S.

With Rare Resolve, X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs.

We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

Accredo is a specialty pharmacy that serves patients with complex and chronic health conditions, including cancer, hepatitis C, HIV, bleeding disorders and multiple sclerosis.

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients.

Amgen Rare Disease also offers free dihydrorhodamine (DHR) testing for CGD through ARUP Laboratories.